Causing infusion reactions in up to 25% of patients, cetuximab is a human/mouse chimeric antibody that targets the epidermal growth factor receptor EGFR, used in the management of metastatic KRAS wild-type metastatic colorectal cancer and head and neck tumors [110]. Here, EGFR is linked to metastatic colorectal cancer.